Disease · MONDO_0001208
Comparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 25
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ABX464 vs Placebo: deaths from any cause | 6 of 335 | 4 of 170 | 505 | NCT04393038 | Trial comparisons |
| ABX464 vs Placebo: serious adverse events | 36 of 335 | 20 of 170 | 505 | NCT04393038 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 28 | 181 of 231 | 172 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 180 | 90 of 231 | 86 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: deaths from any cause | 90 of 231 | 86 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 5 | 146 of 231 | 129 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 90 | 86 of 231 | 83 of 230 | 461 | NCT06729606 | Trial comparisons |
| Aviptadil + SOC vs Placebo + SOC: serious adverse events | 25 of 231 | 23 of 230 | 461 | NCT06729606 | Trial comparisons |
| ABX464 vs Placebo: Rate of Patients Hospitalized | 23 of 203 | 11 of 102 | 305 | NCT04393038 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 28 | 36 of 44 | 34 of 43 | 87 | NCT06729593 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 180 | 19 of 44 | 21 of 43 | 87 | NCT06729593 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: deaths from any cause | 19 of 44 | 21 of 43 | 87 | NCT06729593 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: Number of Participants With a Safety Outcome Through Day 5 | 25 of 44 | 25 of 43 | 87 | NCT06729593 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: Number of Participants Who Died Through Day 90 | 17 of 44 | 20 of 43 | 87 | NCT06729593 | Trial comparisons |
| Remdesivir + SOC vs Placebo + SOC: serious adverse events | 9 of 44 | 2 of 43 | 87 | NCT06729593 | Trial comparisons |
| Dexmedetomidine vs Placebo: serious adverse events | 0 of 18 | 0 of 18 | 36 | NCT00871624 | Trial comparisons |
| Sedative Without Ketamine vs Sedative With Ketamine: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT01938079 | Trial comparisons |
| Tenecteplase vs Placebo: Number of Participants With In-hospital Deaths at 14 Days | 2 of 8 | 1 of 5 | 13 | NCT04505592 | Trial comparisons |
| Tenecteplase vs Placebo: Number of Participants Free of Respiratory Failure | 5 of 8 | 2 of 5 | 13 | NCT04505592 | Trial comparisons |
| Tenecteplase vs Placebo: Number of Participants With New-onset Renal Failure | 0 of 8 | 3 of 5 | 13 | NCT04505592 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001208/comparisons